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TO THE EDITOR
In the October issue of this journal,
De Giorgi et al. (2010) present a novel
morphological approach for the enrich-
ment and visualization of circulating
tumor cells (CTCs) by trapping cells larger
in size than a leukocyte in a filter. The
topic is of great interest as CTCs are
potential precursors of metastases and
their detection is likely to be of prognostic
value in melanoma (Mocellin et al., 2006).
We wish to comment on two aspects
of the article.
First, the authors are wrong in their
statement that in ‘‘cutaneous melanoma
patients CTCs have been studied only by
means of real time RT-PCR’’ (introduction
page 2440). We recently presented an
immunomagnetic approach for the en-
richment and detection of melanoma
chondroitin sulfate proteoglycan (MCSP)-
positive circulating melanoma cells
(Ulmer et al., 2004; Ulmer and Fierlbeck,
2006). We showed that frequencies
of CTCs were stage dependent and
were associated with the tumor load of
the patient. The detection of two or more
CTCs was associated with a reduced
survival in patients with metastatic dis-
ease.
Second, we suggest that any method
used for CTC detection should provide
unambiguous evidence for the malig-
nant nature of the isolated cells. Precise
criteria for defining a cell as CTC
should be applied. CTCs detected by
our immunomagnetic assay had geno-
mic changes typical of malignant mela-
noma. All cells strongly expressed the
MCSP antigen and showed the morpho-
logical criteria for tumor cells (Figure 1).
De Giorgi et al. (2010) used morpho-
logical criteria (nucleo-cytoplasmatic
ratioX50%, hyperchromatic nucleus,
and irregular nuclear shape) in addition
to the size of the cell to define
a cell as CTC. This was supported by
positivity for immunohistochemical
markers (S100, Mart 1 and HMB45)
and tyrosinase messenger RNA as shown
by real-time PCR.
Abbreviations: CTC, circulating tumor cell; MCSP, melanoma chondroitin sulfate proteoglycan;
RT-PCR, reverse transcription-PCR
1774 Journal of Investigative Dermatology (2011), Volume 131
A Ulmer and G Fierlbeck
Circulating Melanoma Cells
However, the cells shown by the
authors after S100 and HMB45 staining
(Figure 1 in their article, second line,
first and third pictures) obviously do not
fulfill the morphological criteria for
tumor cells mentioned above. Thus,
the S100-positive cell (second line, first
picture) certainly does not have a
nucleo-cytoplasmatic ratio of at least
50%. Neither the S100-positive nor the
HMB45-positive structure (second line,
third picture) has a nucleus typical of a
malignant cell. The HMB45-positive
structure is surrounded by unstained
debris and might even represent an
artifact. Additionally, we wonder how
the authors proceeded if they trapped a
single cell in the filter. They state that
due to the weak and often less diffuse
staining intensity of the CTCs in com-
parison with control cells, more than
one marker may be required to con-
clusively identify cells filtered as CTCs.
Did they perform hematoxylin and
eosin staining (for evaluation of mor-
phology), S100, HMB45, and Melan A
immunocytology (for confirmation of
the melanocytic origin), and CD45
staining (to exclude cells of hemato-
poietic origin) on a single cell?
A gold standard for detecting intact
circulating melanoma cells does not exist.
However, we suggest that all methods for
CTC detection should include a careful
workup with respect to specificity. Criter-
ia for the evaluation of circulating cells
should be clearly defined.
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Figure 1. Circulating melanoma cells. (a–c) Examples of melanoma chondroitin sulfate proteoglycan-
positive cells detected in peripheral blood from melanoma patients after immunomagnetic cell sorting
(alkaline phosphatase-anti-alkaline phosphatase (APAAP), neofuchsin; original magnification 100,
bar¼ 10 mm). Circulating tumor cells may be clearly distinguished from surrounding leukocytes by
positive immunostaining (red color) and by morphology.
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